LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

Search

Harvard Bioscience Inc

Slēgts

SektorsVeselības aprūpe

0.54 -8.47

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

0.53

Max

0.6

Galvenie mērījumi

By Trading Economics

Ienākumi

1.1M

-1.2M

Pārdošana

141K

21M

Peļņas marža

-5.978

Darbinieki

330

EBITDA

1M

1.2M

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 12. marts

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-1.9M

24M

Iepriekšējā atvēršanas cena

9.01

Iepriekšējā slēgšanas cena

0.54

Ziņu noskaņojums

By Acuity

17%

83%

23 / 352 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

Harvard Bioscience Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 11. febr. 23:47 UTC

Karstas akcijas

Stocks to Watch: AppLovin, Cisco, Cognex, Pilgrim's Pride

2026. g. 11. febr. 22:59 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Grab Holdings to Buy U.S.-Based Stash Financial

2026. g. 11. febr. 23:54 UTC

Peļņas

McDonald's Says Its Value Campaign Is Paying Off -- 2nd Update

2026. g. 11. febr. 23:50 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 11. febr. 23:50 UTC

Tirgus saruna

Nikkei May Rise on Hopes for Takaichi's Economic Steps -- Market Talk

2026. g. 11. febr. 23:49 UTC

Peļņas

Singtel: Key Focus Areas Are Strengthening Core Businesses, Scaling Growth Engines, Building Momentum Across Regional Associates >Z74.SG

2026. g. 11. febr. 23:45 UTC

Peļņas

Singtel: Net Exceptional Gain of S$1.15B in 3Q Primarily From Sale of Partial Stake in Bharti Airtel>Z74.SG

2026. g. 11. febr. 23:42 UTC

Peļņas

Singtel 3Q Underlying Net Profit S$744M Vs. S$680M >Z74.SG

2026. g. 11. febr. 23:41 UTC

Peļņas

Singtel 3Q Net S$1.89B Vs. Net S$1.32B >Z74.SG

2026. g. 11. febr. 23:40 UTC

Peļņas

Singtel 3Q Operating Revenue S$3.66B Vs. S$3.63B >Z74.SG

2026. g. 11. febr. 23:35 UTC

Tirgus saruna

Gold Falls on Prospects of Long Fed Pause -- Market Talk

2026. g. 11. febr. 23:18 UTC

Tirgus saruna

AppLovin CEO Looks to Soothe Concerns Over AI, Competition -- Market Talk

2026. g. 11. febr. 23:14 UTC

Tirgus saruna

RBA Governor Faces Barrage of Questions About Govt Spending -- Market Talk

2026. g. 11. febr. 22:59 UTC

Peļņas

Kakao 2025 Net KRW525.72B Vs. Loss KRW161.87B >035720.SE

2026. g. 11. febr. 22:59 UTC

Peļņas

Kakao 2025 Oper Pft KRW732.04B Vs. Pft KRW460.21B >035720.SE

2026. g. 11. febr. 22:59 UTC

Peļņas

Kakao 2025 Rev KRW8.099T Vs. KRW7.872T >035720.SE

2026. g. 11. febr. 22:58 UTC

Peļņas

Kakao 4Q Net Loss Missed FactSet-Compiled Consensus

2026. g. 11. febr. 22:57 UTC

Peļņas

Kakao 4Q Loss KRW39.30B Vs. Loss KRW395.21B >035720.SE

2026. g. 11. febr. 22:54 UTC

Peļņas

Kakao 4Q Oper Pft KRW203.45B Vs. Pft KRW75.43B >035720.SE

2026. g. 11. febr. 22:53 UTC

Peļņas

Kakao 4Q Rev KRW2.133T Vs. KRW1.957T >035720.SE

2026. g. 11. febr. 22:47 UTC

Peļņas

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

2026. g. 11. febr. 22:47 UTC

Peļņas

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

2026. g. 11. febr. 22:23 UTC

Peļņas

Grab Holdings Expects to Close Stash Acquisition in 3Q of 2026 >GRAB

2026. g. 11. febr. 22:22 UTC

Peļņas

Grab Holdings to Acquire U.S. Digital Financial Services Company Stash Financial >GRAB

2026. g. 11. febr. 22:22 UTC

Peļņas

Grab Holdings Sees FY26 Adj Ebitda $700M to $720M >GRAB

2026. g. 11. febr. 22:19 UTC

Peļņas

Grab Holdings Sees FY26 Rev $4.04B to $4.10B >GRAB

2026. g. 11. febr. 22:18 UTC

Peļņas

Grab Holdings 4Q Adj Ebitda $148.0M Vs. $97.0M >GRAB

2026. g. 11. febr. 22:18 UTC

Peļņas

Grab Holdings 4Q Net $153.0M Vs. Net $11.0M >GRAB

2026. g. 11. febr. 22:18 UTC

Peļņas

Grab Holdings 4Q Oper Pft $52.0M Vs. $2.0M >GRAB

2026. g. 11. febr. 22:16 UTC

Peļņas

Grab Holdings 4Q Rev $906.0M Vs. $764.0M >GRAB

Salīdzinājums

Cenas izmaiņa

Harvard Bioscience Inc Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

0

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

0.3 / 0.3401Atbalsts un pretestība

Īstermiņā

Weak Bearish Evidence

Vidējā termiņā

No Evidence

Ilgtermiņā

No Evidence

Noskaņojums

By Acuity

23 / 352 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
help-icon Live chat